Keros Therapeutics, Inc.
KROS
$14.91
$0.151.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 111.17% | 102.63% | -22.46% | -27.45% | -32.81% |
| Total Depreciation and Amortization | 30.77% | 40.11% | 50.80% | 64.60% | 70.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.13% | 16.04% | 21.02% | 24.71% | 44.81% |
| Change in Net Operating Assets | 74.50% | 120.37% | -331.58% | 185.72% | -24.89% |
| Cash from Operations | 138.27% | 133.27% | -29.20% | -16.46% | -29.42% |
| Capital Expenditure | 16.49% | 33.99% | 21.63% | 4.00% | -23.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 16.49% | 33.99% | 21.63% | 4.00% | -23.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.59% | 2.97% | 119.09% | 125.46% | 4.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.90% | 44.76% | -382.98% | -357.02% | -380.46% |
| Cash from Financing | 0.71% | 3.04% | 118.95% | 125.30% | 4.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 239.92% | 206.20% | 340.56% | 402.62% | -21.32% |